Aptiom Tablet
Product Images NDC 63402-208

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Aptiom (NDC 63402-208). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sumitomo Pharma America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel – 200 mg Sample Wallet (Apt03 0010 12)

This package contains a medication named Aptiom (eslicarbazepine acetate) in tablet form with a usual dosage of taking it by mouth. The package contains 7 tablets with a dosage of 200mg per tablet. The medication is intended for professional sample use only and is not for sale or reimbursement. The text also includes some unreadable characters and a code for GMO verification.*

FDA Label Image

Principal Display Panel – 400 mg Sample Wallet (Apt03 0010 13)

This is a description of a medication package for Aptiom, which contains tablets of 400mg of eslicarbazepine acetate, manufactured by Sunovion. The package also includes a medication guide which is to be given to each patient.*

FDA Label Image

Principal Display Panel – 600 mg Sample Wallet (Apt03 0010 14)

This is a medication called "Aptiom" which contains tablets of eslicarbazepine acetate. The medication is supposed to be taken orally once a day as per the prescribed dosage or as directed by a medical professional. The tablets should be stored at a temperature range of 20°C to 25°C and should be kept in a non-varnish area. The package contains seven tablets and is not intended for sale or reimbursement purposes. There is additional information on dosage and precautions included in the enclosed Medication Guide.*

FDA Label Image

Principal Display Panel – 800 mg Sample Wallet (Apt03 0010 15)

This is a label of medication named Aptiom (Eslicarbazepine Acetate) Tablets of 800mg. The package contains 7 tablets, and the medication is prescribed only. The label also includes certain instructions for the dispenser.*

FDA Label Image

Principal Display Panel – Titration Sample Pack Wallet (Apt03 0010 16)

FDA Label Image

Principal Display Panel – 200 mg Sample Carton (Apt03 0010 17)

FDA Label Image

Principal Display Panel – 400 mg Sample Carton (Apt03 0010 18)

FDA Label Image

Principal Display Panel – 600 mg Sample Carton (Apt03 0010 19)

FDA Label Image

Principal Display Panel – 800 mg Sample Carton (Apt03 0010 20)

This appears to be information related to a medication called Aptiom, specifically the 800 mg dosages available in tablet form. It also mentions the active ingredient, eslicarbazepine acetate. However, without additional context or formatting, it is difficult to provide a more comprehensive description.*

FDA Label Image

Principal Display Panel – Titration Sample Pack Carton (Apt03 0010 21)

The text seems to be a mix of gibberish and specific medical terms, drug names and dosages. It appears to be a list of tablets and packs of medication, along with a warning against selling or reimbursement. However, there isn't enough coherent information to provide a useful description.*

FDA Label Image

Apt03 0012 08

FDA Label Image

Apt03 0012 09

FDA Label Image

Apt03 0012 10

FDA Label Image

Apt03 0012 11

FDA Label Image

Apt03 0013 01

FDA Label Image

Apt03 0013 02

FDA Label Image

Apt03 0013 03

This text appears to be a list of different medications, doses, and recommendations related to changes in dosage and fold change. It also includes a graph with numbers on the x-axis and y-axis, indicating a change in "slcarbazepine" relative to a reference. There is a mention of "Caspemsepinn," "Gabapentin," "Lamotrigine," "Leveticacetn," "Pranepasbitas," "AFTION," "Topsrumate," "vaspronce," "Fhanobarbital," and "phencharbital-like ADs (s.g., primidone)." There is not enough information to understand the context or purpose of this information.*

FDA Label Image

Apt03 0013 04

This appears to be a section of a medical report discussing changes in the medications carbamazepine, gabapentin, Brenyeon, and topiramate. The report mentions "Fold Change and 90% CI" but does not provide any specifics on what these changes are. The report also makes a recommendation to adjust the dose of one of the medications and monitor the concentration of another medication. There is a graph showing changes in other drugs relative to a reference point, potentially relating to pharmacodynamic interaction.*

FDA Label Image

Apt03 0013 05

FDA Label Image

Apt03 0013 06

FDA Label Image

Apt03 0013 07

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.